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Introduction
Patent ductus arteriosus (PDA) refers to the persistent patency 
of the ductus arteriosus after birth. In most term infants, the duc-
tus arteriosus closes during the first 48 hours after birth. However, 
in many small preterm infants the ductus remains open allowing 
an increasing systemic-to-pulmonary shunt as the pulmonary vas-
cular resistance falls.
1) In premature infants, the ductus frequently 
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fails to undergo spontaneous closure due to the elevated sensitivi-
ty of the ductal tissue to the dilating effects of prostaglandins and 
low sensitivity to the effects of oxygen.
2) As a result, the ductus of 
preterm infants can remain open for many days, and although it 
may constrict initially, it frequently reopens.
3) PDA has been recogniz-
ed as a cause of significant comorbidity in premature infants. In ad-
dition to pulmonary congestion and heart failure caused by the left-
to-right shunt of PDA, clinical sequelae of the ductal steal of blood 
from the PDA present high risks of intraventricular hemorrhage,
4) br-
onchopulmonary dysplasia,
5) pulmonary hemorrhage,
6) renal hypo-
perfusion,
7) necrotizing enterocolitis, and death.
8) Therefore, early di-
agnosis of hemodynamically significant PDA (hsPDA) allows early 
treatment and probable reduction of morbidity in preterm infants.
6)9) 
Because physical examination may be unreliable for determining 
the presence and magnitude of PDA in premature infants, echo-
cardiography is used to document PDA shunting. However, routine 
echocardiography for the evaluation of PDA in premature infants 
has certain disadvantages, such as high cost, discomfort, disruption 
of the neonatal environment, and limited availability in some cen-
ters.
10) Moreover, the hemodynamic effect of a PDA may be difficult 193 Joon Sik Kim, et al.
http://dx.doi.org/10.4070/kcj.2012.42.3.192 www.e-kcj.org
to determine even by using echocardiography, and the clinical co-
urse cannot be predicted reliably.
11)
B-type natriuretic peptide (BNP) is a cardiac natriuretic hormone, 
mainly produced by the cardiomyocytes and is characterized by di-
uretic, natriuretic and vasodilatatory properties. In particular, BNP is 
produced by ventricular cells in response to volume expansion and 
pressure load and in cardiac heart failure.
12)13) BNP antagonizes the 
renin-angiotensin-aldosterone system, and reduces intravascular 
volume, and ventricular preload and afterload. It has been associat-
ed with the regulation of pulmonary vasculature, possibly including 
the ductus arteriosus.
14)
B-type natriuretic peptide can be a useful bedside screening tool 
for the presence of hsPDA in premature infants.
15) Recent studies 
have further demonstrated the potential of BNP to guide an indo-
methacin therapeutic strategy for these patients.
16) 
We evaluated the clinical usefulness of the measurement of pl-
asma BNP levels in preterm infants. For accurate diagnosis of hsP-
DA, we performed repeated BNP level measurements and determin-
ed the best cut-off value of BNP on day 4 of life and the change in 
BNP level after treatment with indomethacin for predicting hsPDA. 
Subjects and Methods
Subjects
This prospective study was conducted at the neonatal intensive 
care unit of Hallym University Sacred Heart Hospital. Preterm infants 
born at <37 weeks’ gestational age (GA) were eligible for entry into 
the study. The infants were enrolled within 24 hours of birth. Pre-
term infants with congenital anomalies, cardiac abnormalities other 
than patent foramen ovale, and intraventricular hemorrhage oc-
curring before 48 hours of life were excluded from this study. Thirty-
three preterm infants were initially enrolled during a 5-month pe-
riod (from April 2009 to August 2009). The data of 5 infants were 
excluded from analysis because the data were incomplete. Twenty-
eight infants (12 male, 16 female) were eligible for evaluation. Their 
mean GA was 32.7 weeks (range: 28.4-35.8 weeks) and the mean 
birth weight was 1918 g (range: 1080-2830 g). We prospectively 
evaluated the infants for PDA within the first 7 days of life and ad-
ministered indomethacin if hsPDA was diagnosed based on a large 
ductal flow with left to right shunt on color Doppler echocardiography.
Measurement of plasma B-type natriuretic peptide level
Blood samples for BNP level were collected by umbilical venous 
catheter aspiration or from the peripheral vein and were transferred 
into ethylenediaminetetraacetic acid tubes. Blood samples were 
taken on days 1, 4, and 7 after birth. BNP concentrations were de-
tected using a commercial diagnostics system (Aggott achitect BNP 
assay, Abbott Diagnostics, Abbott Park, IL, USA). 
Echocardiography
A GE Vivid 7 Dimension cardiovascular ultrasound machine with 
curvilinear 8 MHz transducer incorporating color-flow, pulsed-wave, 
and continuous-wave Doppler was used (GE Healthcare, Fairfield, CT, 
USA). A two-dimensional color flow Doppler echocardiography was 
performed on all infants within the fourth day of life for assessment 
of PDA and to rule out congenital heart disease. A significant PDA 
was diagnosed based on the presence of a large ductal flow with 
left to right shunt with retrograde flow in the descending aorta, as 
demonstrated on the two-dimensional color Doppler echocardio-
graph.
17-19) To estimate the magnitude of left to right shunting ac-
ross the PDA, a ratio of the diameters of the left atrial to aortic root 
(LA/AO) was evaluated in the parasternal long axis view at the level 
of the aortic valve. The infants with hsPDA were treated with three 
doses of indomethacin.
20) Follow-up echocardiography was perform-
ed on day 8 of life by one investigator to avoid inter-observer vari-
ability.
Diagnosis of hemodynamically significant 
patent ductus arteriosus
Hemodynamically significant PDA was diagnosed if the infant 
fulfilled the echocardiographic criteria and had at least 3 of the 
following 6 clinical signs of cardiovascular dysfunction including 1) 
systolic or continuous murmur at the left sterna edge, 2) increased 
precordial impulse, 3) bounding peripheral pulses, 4) resting tachy-
cardia, 5) unexplained deterioration of the respiratory status, and 6) 
increased pulmonary vascular markings and cardiac enlargement 
or signs of pulmonary edema on the chest radiograph. The echocar-
diographic criteria included 1) LA/AO diameter ratio >1.4. 2) Diastolic 
turbulence (backflow) on the Doppler echocardiograph of the pul-
monary artery, and 3) ductal diameter of PDA >1.4 mm.
21) 
Indomethacin administration
Indomethacin (Indocin®, Merck Sharp and Dohme, West Point, PA, 
USA) was given as a 60-minute intravenous infusion at 24-hour in-
tervals for each course (3 doses). For the initial indomethacin dose, 
0.2 mg/kg was administered to all patients regardless of their age.
22) 
For the second or third dose, 0.1 mg/kg was administered when the 
patient was <48 hours old, and 0.2 mg/kg was administered when 
the patient was 2 to 7 days old, respectively.
Statistical analysis
Statistical analysis was performed using Statistical Package for 
the Social Sciences (SPSS) version 15.0 (SPSS Inc., Chicago, IL, USA). 
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deviation. We used the Fisher’s exact test to compare categorical 
variables and the Mann-Whitney’s rank sum U test to compare con-
tinuous variables. The Mann-Whitney’s rank-sum U test was used 
to calculate the differences of BNP levels between the groups. Re-
ceiver operator characteristic (ROC) analysis was performed to de-
termine the best cut-off values of plasma BNP levels for the detec-
tion of significant PDA. A p<0.05 was considered significant.
Results
Clinical characteristics of infants in the control and 
hemodynamically significant patent ductus arteriosus groups
For a 5-month period, 28 preterm infants (12 male, 16 female) 
were prospectively enrolled in our study. Of the 28 infants, 21 in-
fants had no hsPDA (control group, mean GA: 32.83 weeks; mean 
birth weight: 1930 g). The remaining 7 infants had hsPDA, which re-
quired treatment with indomethacin (hsPDA group, mean GA: 32.18 
weeks; mean birth weight: 1850 g). The characteristics of the infants 
in these 2 groups are summarized in Table 1. No significant differ-
ences were observed in GA, birth weight, sex, or delivery type.
B-type natriuretic peptide levels in the control and 
hemodynamically significant patent ductus arteriosus group
This study showed a significant correlation between BNP levels on 
day 4 of life and presence of PDA in preterm infants (Table 2). On 
day 4 of life, the mean BNP concentration in the hsPDA group was 
significantly higher than that in the control group (median 654.68 
vs. 124.52 pg/mL; p<0.001) (Fig. 1). Seven infants in the hsPDA gr-
oup showed clinical symptoms, such as continuous murmur at the 
left sterna edge, resting tachycardia, and tachypnea. on day 8 of life, 
the 7 infants in the hsPDA group became asymptomatic after the 
administration of 3 doses of indomethacin. All the infants in the 
hsPDA group completed their therapy with a single treatment co-
urse (3 doses), and without the need for a second course of indo-
methacin. At the second echocardiographic evaluation (on day 8 
of life), the ductus of 5 infants in the hsPDA group were closed. In 
the remaining 2 infants with hsPDA, ductal shunt was reduced and 
ductal closure was confirmed 7 days later. After treatment with in-
domethacin, the BNP levels in the hsPDA group decreased signifi-
cantly (median 654.68 vs. 288.48 pg/mL; p<0.001). 
In the control group 18 infants demonstrated a progressive fall in 
plasma BNP level from day 1 to day 7. The remaining 3 control gr-
oup infants demonstrated an initial fall and subsequent rise in the 
plasma BNP level. Upon reviewing the clinical records of these lat-
ter infants, they had late onset sepsis between day 4 and day 7 of 
life. All subjects in the hsPDA group had no sepsis by day 7 of life. In 
this study, there was no preterm infant with pulmonary hypertension. 
At the first echocardiographic evaluation, a significant correla-
tion was observed between the LA/AO diameter ratios and BNP 
levels (r=0.812; p<0.001) (Fig. 2).
Table 1. Characteristics of infants in the control and hsPDA groups
Control group
(n=21)
hsPDA group
(n=7)
p
Gestational age (week) 32.83±2.22 32.18±1.67 0.376
Birth weight (kg) 1.93±0.49 1.85±0.48 0.640
Male/Female 9/12 3/4 NS
Caesarean section (%) 14 (67) 5 (71) NS
Values are expressed as numbers (%) of infants or means±SD. NS: not signifi-
cant, hsPDA: hemodynamically significant patent ductus arteriosus
Table 2.  BNP levels in the control and hsPDA groups                     (pg/mL)
Control group
(mean)
hsPDA group
(mean)
p
1 day 290.86±182.91 525.92±191.85 0.056
4 day 124.52±78.02 654.68±257.27 <0.001
7 day 75.46±65.16 288.48±158.96 <0.001
Values are expressed as means±SD. hsPDA: hemodynamically significant 
patent ductus arteriosus, BNP: B-type natriuretic peptide 
Fig. 2. Correlation between LA/AO ratio and BNP level. BNP levels correlated 
positively with the LA/AO ratio (r=0.812; p< 0.001). BNP: B-type natriuretic 
peptide. LA: left atrium, AO: aorta.
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Fig. 1. Plasma B-type natriuretic peptide (BNP) values on days 1, 4 and 7 of 
life. PDA: patent ductus arteriosus.
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The area under the ROC curve for the detection of PDA was sta-
tistically significant at 0.998 (95% confidence interval: 0.995-
1.002). The level of plasma BNP on day 4 of life was a highly sensi-
tive indicator of hsPDA (sensitivity 100%; specificity 95%) with a 
cutoff value of 412 pg/mL (Fig. 3).
Discussion
B-type natriuretic peptide has a 32 amino acid ring structure. It 
acts on a cyclic guanosine monophosphate-coupled receptor via a 
transmembrane domain.
23) The ventricles of the heart are the main 
site of BNP synthesis and release in response to volume and pres-
sure loading, as well as ventricular stress.
12)13) 
B-type natriuretic peptides have a major role in the screening and 
diagnosis of cardiac disease and monitoring of the treatment resp-
onse in children and adults. Recent studies have concentrated on 
the potential use of these markers in pediatric and neonatal medi-
cine. In all neonates, BNP concentrations increase on day 1 of life and 
show a typical peak, even in the absence of a significant patent of 
the ductal arteriosus, and subsequently decrease with chronological 
age.
24) The BNP levels in preterm infants were higher than in healthy 
term infants during the first few days after birth. In particular, when 
PDA is present in preterm infants, the BNP concentration is abnor-
mally high and reflects the magnitude of shunting through the PDA. 
Holmström et al.
11) reported that plasma levels of natriuretic pep-
tides in preterm infants are strongly related to the hemodynamic in-
fluence of PDA. Since then, plasma natriuretic peptide levels, in-
cluding increased BNP levels, were studied to determine the pres-
ence of hsPDA in preterm infants. Flynn et al.
10) showed that BNP 
levels strongly correlated with ductal size in premature neonates. 
We measured the plasma BNP levels in preterm infants during the 
first 7 days of life. On day 4 of life, plasma BNP levels in infants with 
hsPDA were significantly higher than in infants without hsPDA, al-
though the primary limitation of this study was its small sample size. 
The best cutoff BNP concentration on day 4 of life was 412 pg/mL; 
sensitivity was 100%, and specificity was 95%. Flynn et al.
10) showed 
that the best cutoff of BNP concentration is 300 pg/mL and a lower 
cutoff of 105 pg/mL for infants at >2 days of life. Lee et al.
25) sh-
owed that the best cutoff at 24 hours of age is 468.5 pd/mL and at 
48 hours of age is 935 pg/mL. In another study, the best cutoff BNP 
concentration on day 3 of life was 1110 pg/mL.
26) 
Hsu et al.
27) reported that the mean BNP levels decreased signifi-
cantly in response to indomethacin. They classified as responders 
and non-responders in preterm infants with PDA. After treatment 
with indomethacin, the mean BNP levels in the responders decreased 
significantly from the baseline 24 hours after the final dose, wh-
ereas the BNP levels in the non-responders did not change signifi-
cantly. We could not conduct a comparative study of indomethacin 
responsiveness because all the hsPDAs closed after indomethacin 
administration. Moreover, in our study, the sample size was smaller, 
the birth weights were larger, and the GA was higher than in the pre-
vious study. However, our results demonstrated that the mean BNP 
level in the hsPDA group decreased significantly after indomethacin 
treatment. Moreover, significantly decreasing BNP levels predicted 
a good response to indomethacin treatment and ductal closure.
In this study, 3 infants in the control group, with increased BNP 
concentration from day 4 to 7, had late onset sepsis but a lower 
mean BNP concentration on day 7 compared with the hsPDA group. 
In animal studies, plasma BNP levels have been shown to rise with 
induced endotoxemia, and the pro-inflammatory cytokine interleu-
kin-6 has been linked with BNP production.
28) In patients with severe 
sepsis or septic shock, BNP levels are highly elevated. In a compar-
ative study on children with sepsis and those with acute left ven-
tricular dysfunction, BNP levels were found to be higher in the lat-
ter group. Therefore, BNP serves as a marker for cardiac dysfunction 
associated with sepsis in preterm neonates.
29)30) 
Echocardiography is the main method used to detect PDA in new-
borns. Although BNP may not replace echocardiography for the di-
agnosis of PDA, it may obviate the need to perform repeated echo-
cardiography in order to confirm ductal closure after treatment. BNP 
measurement can be used as an adjunct to echocardiography for 
diagnosing PDA. Although it is not a stand-alone test, the BNP as-
say is an immediate method for providing valuable information that 
indicates whether an infant requires intervention for PDA, and de-
termines the clinical course of PDA in a preterm infant. BNP may 
be a useful screening tool for detecting the presence of a PDA in 
premature neonates, because levels of BNP are higher in the pres-
ence of a significant patent ductus. In addition, serial BNP mea-
surements may be of value in assessing the clinical course of PDA 
and a possible alternative to repeated echocardiography in the di-
agnosis and management of PDA in preterm infants.
Fig. 3. Receiver operator characteristic curve determines the B-type natri-
uretic peptide cutoff value for detecting hemodynamically significant patent 
ductus arteriosus in preterm infants.
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